AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to go somewhere in Virginia.

A judge's skeptical questions cut through lawyerly arguments to ask the Indiana Attorney General's Office a question it wouldn't, or couldn't, answer.